SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Trillium Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: Bladerunner17 who wrote (215)10/7/2018 3:19:09 PM
From: Biomaven  Read Replies (1) | Respond to of 294
 
Reasonable piece in TRIL - wouldn't call it particularly negative. The data on CTCL make it an approvable drug at the end of the day, so on that basis alone I think it is cheap and I actually bought more on Friday ahead of ASH data. They still need to figure out combos better, and they really should partner sooner rather than later.

Market worried about another offering here I suspect.

Peter



To: Bladerunner17 who wrote (215)12/19/2018 9:25:30 AM
From: tuck  Respond to of 294
 
Competitor SURF shelves its lagging me too CD47 program. FTSV, apparently having finessed the RBC binding issue remains the serious threat.

Cheers, Tuck



To: Bladerunner17 who wrote (215)2/22/2019 11:18:44 AM
From: scaram(o)uche  Read Replies (2) | Respond to of 294
 
>> what do you think of scaramouche's criticisms of TRIL? <<

Class-act memories of 2/21/2019.........

Jussie Smollette
James Parsons
Jeffrey Epstein
Roger Stone
Nic Stiernholm


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News